| Autor: |
Erskine A. James, Zhi Qing Zhao, John R Curcuru, Rong Hua Zheng, Wei-Wei Zhang, Ning Ping Wang |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
MOJ Drug Design Development & Therapy. 1 |
| ISSN: |
2575-9094 |
| DOI: |
10.15406/mojddt.2017.01.00019 |
| Popis: |
The purpose of this study was to elucidate whether treatment with cyclosporine induces myocardial fibrosis and hypertension that may potentially be mediated by activation of angiotensin II Ang II and induction of inflammation In C BL mice cyclosporine at the doses of mg kg day or mg kg day was administrated by gastric gavage In different groups angiotensin II Ang II AT receptor blocker telmisartan mg kg day or anti inflammatory compound curcumin mg kg day was co administered with cyclosporine Treatment with cyclosporine for weeks did not alter the protein expression including AT and AT receptors monocyte chemotactic protein transforming growth factor beta collagen I and collagen III but increased expression of angiotensin converting enzyme relative to the sham control Interstitial macrophage infiltration and myofibroblast proliferation were not changed by cyclosporine consistent with lack of collagen deposition in the interstitial perivascular regions Co administration of telmisartan or curcumin with cyclosporine also had no effect on any of the parameters measured There was a trend in increase of blood pressure with high dose of cyclosporine alone and decrease of blood pressure when cyclosporine was co administered with telmisartan or curcumin but these changes did not achieve the statistical differences among the groups These data suggest that cyclosporine has no direct effect on myocardial fibrosis and blood pressure in healthy individuals and it may be considered as an adjunctive therapy with commonly used drugs to treat cardiovascular diseases nbsp |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
